Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2023

11-07-2023 | Gaucher Disease | Letter to the Editor

A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma

Authors: A. Rago, G. Palumbo, A. Tordi, S. Bianchi, M. Offidani, T. Caravita di Toritto

Published in: Annals of Hematology | Issue 10/2023

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A et al (2016) European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Hematologica 9:1422–1432
2.
Kazandjian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 6:676–681CrossRef
3.
Szalat R, Munshi NC (2019) Novel agents in multiple myeloma. Cancer J 1:45–53CrossRef
4.
Linari S, Castaman G (2016) Hematological manifestations and complications of Gaucher disease. Expert Rev Hematol 9:51–58CrossRefPubMed
5.
Shiran A, Brenner B, Laor A, Tatarsky I (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72:219–224CrossRefPubMed
6.
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 14:1319–1331CrossRef
7.
Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A (2014) Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 1:214–217
8.
Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S et al (2014) International Myeloma Working Group IMWG consensus on risk stratification in multiple myeloma. Leukemia 2:269–277CrossRef
9.
Rosenbloom BE, Cappellini MD, Weinreb NJ, Dragosky M, Revel-Vilk S, Batista JL et al (2022) Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. Am J Hematol 97:1337–1347CrossRefPubMedPubMedCentral
Metadata
Title
A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma
Authors
A. Rago
G. Palumbo
A. Tordi
S. Bianchi
M. Offidani
T. Caravita di Toritto
Publication date
11-07-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05319-x

Other articles of this Issue 10/2023

Annals of Hematology 10/2023 Go to the issue

Letter to the Editor

One disease, two faces: clonally-related AML and MPDCP with skin involvement

Original Article

Treating relapsed B cell-precursor ALL in children with a setting-adapted mitoxantrone-based intensive chemotherapy protocol (TMH rALL-18 PROTOCOL) — experience from Tata Memorial Hospital, India

Original Article

Recent national trends in outcomes and economic disparities among adult sickle cell disease-related admissions

Original Article

A novel germline hyperactivating JAK2 mutation L604F

Original Article

Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma

Letter to the Editor

Successful treatment of systemic mastocytosis with AML
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits